Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ahSC Augmentation in Severe Peripheral Nerve Injury
NCT05541250Phase 1Recruiting
- Start
- May 2023
- Primary completion
- Sep 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous human Schwann cells in peripheral nerve injury (PNI). Primary endpoint: Incidence of Treatment-related Adverse Events up to 2 years. Started May 2023; status: recruiting.
02
Drugs
autologous human Schwann cells
03
Conditions
peripheral nerve injury (PNI)
Beyond the preview
Go deeper on NCT05541250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05541250.